{"database": "lobbying", "table": "lobbying_activities", "rows": [[1338097, "f81586f9-27ec-4599-997e-efce1e7667e5", "Q4", "KNIGHT CAPITOL CONSULTANTS", 40036301, "GENZYME CORPORATION", 2012, "fourth_quarter", "PHA", "S. 606, Creating Hope Act of 2011, S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act, The Food and Drug Administration Safety and Innovation Act (PL 112-144) and amendments considered, including the Faster Access to Specialized Treatments Act (H.R. 4132) and the Transforming the Regulatory Environment to Accelerate Access to Treatment\n(TREAT) Act (S. 2113).  Assess potential impact of sequestration on public health/food and drug programs (HR 8/PL 112-240).", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2013-01-16T17:26:05.230000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1338097"], "units": {}, "query_ms": 99.66185805387795, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}